0.69
-0.0292(-4.06%)
Currency In USD
| Previous Close | 0.72 |
| Open | 0.69 |
| Day High | 0.72 |
| Day Low | 0.66 |
| 52-Week High | 3 |
| 52-Week Low | 0.57 |
| Volume | 94,902 |
| Average Volume | 1.28M |
| Market Cap | 5.45M |
| PE | -0.79 |
| EPS | -0.87 |
| Moving Average 50 Days | 0.69 |
| Moving Average 200 Days | 0.91 |
| Change | -0.03 |
If you invested $1000 in Adial Pharmaceuticals, Inc. (ADIL) since IPO date, it would be worth $6.81 as of May 26, 2025 at a share price of $0.69. Whereas If you bought $1000 worth of Adial Pharmaceuticals, Inc. (ADIL) shares 5 years ago, it would be worth $17.24 as of May 26, 2025 at a share price of $0.69.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire Inc.
May 15, 2025 12:30 PM GMT
GLEN ALLEN, Va., May 15, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and re
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study
GlobeNewswire Inc.
May 13, 2025 12:30 PM GMT
Milestone Achieved as Adovate Initiates First-in-Human Study for Novel Asthma Therapy Targeting Underserved, Multi-Billion Dollar MarketGlen Allen, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Co
Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration
GlobeNewswire Inc.
May 08, 2025 12:30 PM GMT
Meeting to Take Place on July 25, 2025 Meeting’s Purpose is To Discuss Upcoming Clinical Development Plan and Protocol Designs GLEN ALLEN, Va., May 08, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”),